Olema Pharmaceuticals, Inc. (OLMA) Dividend History

Olema Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for women’s cancers. Founded to leverage innovative science, the company aims to address unmet medical needs in breast and ovarian cancers through novel approaches and personalized treatments.

780 Brannan Street, San Francisco, CA, 94103
Phone: (415) 651-3316
Website: https://www.olema.com

Dividend History

Olema Pharmaceuticals, Inc. currently does not pay dividends

Company News

  • Olema Oncology announced the selection of a 90 mg once-daily dose of palazestrant for its Phase 3 OPERA-01 monotherapy trial and OPERA-02 combination trial with ribociclib. The company will present a trial-in-progress poster for OPERA-01 at the ASCO 2025 Annual Meeting.

    GlobeNewswire Inc.
  • U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Shares of Eaton Corporation plc (NYSE: ETN) rose sharply during Thursday’s session after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance. Eaton posted adjusted earnings of $2.55 per share, beating market estimates of $2.47 per share. The company’s quarterly sales came in at $5.97 billion versus expectations of $5.91 billion, according to data from Benzinga Pro. Eaton shares gained 6.2% to $261.48 on Thursday. Here are some other big stocks recording gains in today’s session. Cimpress plc (NASDAQ: CMPR) shares surged 28.8% to $96.90 after the company reported better-than-expected second-quarter financial results and said the board authorized the repurchase of up to $150 million of company shares. Nextracker Inc. (NASDAQ: NXT) rose gained 18.8% to $53.79 after the company reported better-than-expected third-quarter financial results. SunPower Corporation (NASDAQ: SPWR) gained 18.1% to $3.5791. Corteva, Inc. (NYSE: CTVA) rose 16.2% to $52.84 after the company reported better-than-expected quarterly financial results, issued 2024 guidance and announced a $1 billion ...

    Benzinga
  • Olema's (OLMA) shares surge on the successful development of its lead candidate in metastatic breast cancer indication.

    Zacks Investment Research
    Featured Companies: ACAD PFE
Page data last updated 07/23/2025 17:47:04 UTC